[2] Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022;8(8):1177–1183. [3] Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters ...
在这项研究中,他们揭示了HER2低表达乳腺癌的异质性,并强调需要对激素受体状态和分子亚型进行更精确的分层。 相关论文于当地时间8月22日在线发表于国际知名期刊《自然-通讯》(Nature Communications),题为“Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast ca...
Find information about Herceptin® (trastuzumab), a treatment for HER2+ early and metastatic breast cancer and stomach cancer/GEJ. See full safety & Boxed Warnings for more information.
1. 乳腺癌信息管理系统确保高质量的真实世界研究数据 四川大学华西医院乳腺癌信息管理系统(Breast Cancer Information Management System,BCIMS)始建于2008年。根据最新的诊疗指南,兼顾临床实践,由乳腺肿瘤内科、乳腺外科、放疗科、病理科、影像科等多学科专家团队共同设计与创建了该系统,并不断更新。多学科专家团队自主设...
目前FDA批准了五种曲妥珠单抗生物类似物进入美国市场,其他药物正在开发中(见相关链接: https://www.fda.gov/drugs/biosimi-lars/biosimilar-productinformation)。曲妥珠单抗-dkst (OGIVRI,MYL1401O)是首个获得FDA批准(2017年)用于HER2过表达BC和胃肠道(GI)...
Financial support was provided by Breast Cancer Research Foundation. Author information Authors and Affiliations Department of Medicine, Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC, USA Sandra M. Swain Sarah Cannon Research Institute, Nashville, TN, USA Mythili ...
6.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer 7.Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F...
[6]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer [7]. https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/us-fda-ap...
[21]Trastuzumab deruxtecan(T-DXd)in patients(Pts)with HER2-mutant metastatic non-small cell lung cancer(NSCLC):Interim results from the phase 2 DESTINY-Lung02 trial.2022 ESMO LBA55. [22]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzuma...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...